Synergism between rapamycin and host-nonreactive veto CTLs
. | Experiment no. . | . | . | . | . | . | . | Average . | . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . | 7 . | Ratio . | % . | P . | ||||||||
| Irradiation control, 11 Gy | 0/7 | 0/7 | 0/7 | 0/7 | 0/7 | 0/5 | 0/7 | 0/47 | 0 | NA | ||||||||
| Balb/c-Nu/BM 2 × 106 | 6/7 | 7/7 | 6/7 | 6/7 | 8/8 | 5/5 | 7/7 | 45/48 | 94 ± 7 | NA | ||||||||
| Balb/c-Nu/BM 2 × 106 + rapamycin* | — | 6/7 | — | — | — | — | — | 6/7 | 85.7 | NA | ||||||||
| Balb/c-Nu/BM 2 × 106 + HTC 1 × 104 | 1/7 | 0/7 | 0/7 | 1/7 | 0/7 | 0/5 | 0/7 | 2/47 | 4.1 ± 6.5 | < .01 | ||||||||
| Balb/c-Nu/BM 2 × 106 + HTC 1 × 104 + rapamycin* | 1/7 | 0/7 | 0/6 | 0/7 | 1/7 | 0/5 | 0/7 | 2/46 | 4.1 ± 6.5 | < .01 | ||||||||
| Balb/c-Nu/BM 2 × 106 + HTC 1 × 104 + CTL (Balb/c → FVB) 10 × 106 | 0/7 | 0/7 | 0/7 | 3/7 | 3/7 | 0/6 | 2/7 | 8/48 | 16.3 ± 19 | < .01 | ||||||||
| Balb/c-Nu/BM 2 × 106 + HTC 1 × 104 + CTL (Balb/c → FVB) 10 × 106 + rapamycin* | 6/7 | 3/7 | 2/7 | 4/6 | 6/7 | 6/7 | 7/7 | 34/47 | 73 ± 25 | .05 | ||||||||
. | Experiment no. . | . | . | . | . | . | . | Average . | . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . | 7 . | Ratio . | % . | P . | ||||||||
| Irradiation control, 11 Gy | 0/7 | 0/7 | 0/7 | 0/7 | 0/7 | 0/5 | 0/7 | 0/47 | 0 | NA | ||||||||
| Balb/c-Nu/BM 2 × 106 | 6/7 | 7/7 | 6/7 | 6/7 | 8/8 | 5/5 | 7/7 | 45/48 | 94 ± 7 | NA | ||||||||
| Balb/c-Nu/BM 2 × 106 + rapamycin* | — | 6/7 | — | — | — | — | — | 6/7 | 85.7 | NA | ||||||||
| Balb/c-Nu/BM 2 × 106 + HTC 1 × 104 | 1/7 | 0/7 | 0/7 | 1/7 | 0/7 | 0/5 | 0/7 | 2/47 | 4.1 ± 6.5 | < .01 | ||||||||
| Balb/c-Nu/BM 2 × 106 + HTC 1 × 104 + rapamycin* | 1/7 | 0/7 | 0/6 | 0/7 | 1/7 | 0/5 | 0/7 | 2/46 | 4.1 ± 6.5 | < .01 | ||||||||
| Balb/c-Nu/BM 2 × 106 + HTC 1 × 104 + CTL (Balb/c → FVB) 10 × 106 | 0/7 | 0/7 | 0/7 | 3/7 | 3/7 | 0/6 | 2/7 | 8/48 | 16.3 ± 19 | < .01 | ||||||||
| Balb/c-Nu/BM 2 × 106 + HTC 1 × 104 + CTL (Balb/c → FVB) 10 × 106 + rapamycin* | 6/7 | 3/7 | 2/7 | 4/6 | 6/7 | 6/7 | 7/7 | 34/47 | 73 ± 25 | .05 | ||||||||
HTC indicates host (C3H/HeJ) T cells (CD4+ and CD8+); —, not done; and NA, not applicable.
Rapamycin 10 μg/mouse/day.